Obtaining Varied Actionable Genetic Variations in the Middle East
Implementation is lagging in many parts of the world, including the Middle East, mainly due to the lack of data on the distribution of actionable pharmacogenomic variations.
From the Qatar Genome Research Consortium, this comprehensive study of the distribution of actionable genetic variation affecting drugs in a Middle Eastern population has potential to ensure implications for preemptive pharmacogenomic implementation in the region and beyond.
This analysis consisted of an observational longitudinal cohort of 6218 apparently healthy adult Qatari individuals, consented and recruited by the Qatar Biobank and whose genomes were sequenced as part of the first phase of the Qatar Genome Program, and is one we recommend our memebers and affiliates look over.
